ipharmacenter Consulting services

Rank Brand Company Indications Revenues $ billion 1 Keytruda Merck Melanoma, NSCLC, HNSCC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $31.7 2 Darzalex Johnson and Johnson Multiple myeloma $14.5 3 Opdivo Bristol Myers Squibb Melanoma, NSCLC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $10.0 4 Tagrisso AstraZeneca EGFR positive NSCLC $7.2 5 Imfinzi AstraZeneca NSCLC, SCLC, locally advanced or metastatic biliary tract canc

Bimzelx Leads in Head-to-Head PsA Trial, Surpassing Skyrizi at Week 16 Bimzelx (bimekizumab) has demonstrated greater efficacy than Skyrizi (risankizumab) in treating psoriatic arthritis, based on Week 16 results from the BE BOLD trial. What is the efficacy comparison of Bimzelx vs Skyrizi in psoriatic arthritis? At Week 16, 49.1% of patients treated with bimekizumab achieved the ACR50 primary endpoint, compared with 38.4% of those receiving risankizumab, confirming statistic